Compare Bristol-Myers Squibb Co (BMY) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Wells Fargo & Co — how do they compare? Bristol-Myers Squibb Co trades at $58.71 (market cap $116.30B), while Wells Fargo & Co trades at $86.9 (market cap $258.30B). The key difference: Wells Fargo & Co is far larger — about 2.2× Bristol-Myers Squibb Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | WFC | |
|---|---|---|
Market Cap | $116.30B | $258.30B |
Sector | Health | Financials |
52-Week High | $62.37 | $96.40 |
52-Week Low | $42.60 | $73.42 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | 2.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Wells Fargo (WFC) trades at $87.70, up 0.67% with a bullish technical outlook. The stock shows strong fundamentals with Q2 2026 EPS beating estimates at $2.00 versus $1.73 expected, driven by net interest income and fee growth. Revenue trends upward from $83.7B in 2025 to projected $85.0B in 2026, while net income margin remains robust at 25.5%. Recent news highlights the bank's $1B+ technology investment in AI tools for wealth management and a healthy investment banking pipeline.
The outlook is positive with a consensus price target of $99.10 offering 13% upside. Key opportunities include continued earnings momentum and efficiency gains from tech investments. Risks involve expense pressures, macroeconomic sensitivity, and competitive banking sector dynamics. Analyst sentiment is mixed with 45% buy ratings but near-term execution on guidance will be critical for sustained outperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
